DexCom Price Target Cut to $75.00/Share From $120.00 by Morgan Stanley
BTIG Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $120
Oppenheimer Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $115
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $145
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)
DexCom Analyst Ratings
Dexcom (DXCM) Gets a Buy From RBC Capital
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ovid Therapeutics (OVID) and Dexcom (DXCM)
Raymond James Adjusts Price Target on DexCom to $115 From $160
Dexcom: A Cautious Hold Amid Competitive Challenges and Operational Headwinds
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $145
DexCom Analyst Ratings
Dexcom's Market Leadership and Strategic Growth Opportunities Affirm Buy Rating
Leerink Adjusts Price Target on DexCom to $151 From $161
DexCom Analyst Ratings
Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $120
Morgan Stanley Cuts Price Target on DexCom to $120 From $132, Keeps Equalweight Rating
DexCom Analyst Ratings
Stifel Maintains Buy on DexCom, Lowers Price Target to $132
Stifel Nicolaus Remains a Buy on Dexcom (DXCM)